Brief: Seagen And Lava Therapeutics Announce Exclusive Worldwide License Agreement To Advance Lava-1223, A Preclinical Gamma Delta Bispecific T Cell Engager For EGFR-Expressing Solid Tumors

LAVA Therapeutics NV

26/09/2022 14:24

Sept 26 (Reuters) - LAVA Therapeutics NV  LVTX.O :
    * SEAGEN AND LAVA THERAPEUTICS ANNOUNCE EXCLUSIVE WORLDWIDE
LICENSE AGREEMENT TO ADVANCE LAVA-1223, A PRECLINICAL GAMMA
DELTA BISPECIFIC T CELL ENGAGER FOR EGFR-EXPRESSING SOLID TUMORS
    * SEAGEN AND LAVA THERAPEUTICS ANNOUNCE EXCLUSIVE WORLDWIDE
LICENSE AGREEMENT TO ADVANCE LAVA-1223, A PRECLINICAL GAMMA
DELTA BISPECIFIC T CELL ENGAGER FOR EGFR-EXPRESSING SOLID TUMORS
    * SEAGEN INC - LAVA TO RECEIVE UPFRONT PAYMENT OF $50
MILLION,
WITH POTENTIAL FOR MILESTONES OF UP TO APPROXIMATELY $650
MILLION AND ROYALTIES
    * SEAGEN INC - SEAGEN ALSO HAS AN OPTION TO NOMINATE UP TO
TWO
ADDITIONAL TUMOR TARGETS FOR BISPECIFICS USING LAVA'S
PROPRIETARY GAMMABODY™ PLATFORM
    * SEAGEN INC - SEAGEN TO DEVELOP AND COMMERCIALIZE LAVA-1223
    * SEAGEN INC - UNDER TERMS OF AGREEMENT, SEAGEN WILL RECEIVE
AN
EXCLUSIVE GLOBAL LICENSE FOR LAVA-1223

Source text for Eikon:  ID:nGNX1XKmFV 
Further company coverage:  LVTX.O 
 ((Reuters.Briefs@thomsonreuters.com;;))